| Politician | Action | Description | Traded |
|---|---|---|---|
| Buy | Agios Pharmaceuticals, Inc. | Aug 20, 2026 | |
| Sell | AGIO PHARMACEUTICALS LIMITED | Apr 2, 2026 | |
| Buy | Agios Pharmaceuticals, Inc. | Mar 3, 2026 | |
| Buy | Agios Pharmaceuticals, Inc. | Dec 11, 2025 | |
| Buy | Agios Pharmaceuticals, Inc. | Apr 17, 2025 | |
| Buy | Agios Pharmaceuticals, Inc. | Jan 29, 2025 | |
| Buy | Agios Pharmaceuticals, Inc. | Jan 24, 2024 | |
| Buy | AGIOS PHARMACEUTICALS INC CM | Aug 23, 2021 | |
| Sell | Agios Pharmaceuticals Inc | Jul 2, 2021 | |
| Sell | Agios Rocketdyne Holdings, I | Aug 19, 2019 |
This page tracks congressional stock trading activity in Agios Pharmaceuticals, Inc. (AGIO) in the Healthcare sector. Disclosed Capitol has indexed 14 disclosed congressional trades involving AGIO. Every trade is sourced from official STOCK Act financial disclosure filings — the same primary records the Senate and House are required to publish. The full trade list with politician names, transaction types, amount ranges, and disclosure dates is below, alongside cross-references to any related lobbying activity, federal contracts, and committee assignments.
As of September 2026 — Disclosed Capitol has tracked 14 disclosed congressional trades in Agios Pharmaceuticals, Inc. (AGIO) — 4:2 sell-heavy ratio — led by Gilbert Cisneros (D).
| Date | Politician | Party | Action | Amount |
|---|---|---|---|---|
| Aug 20, 2026 | Gilbert Cisneros | D | Buy | $1,001 - $15,000 |
| Apr 2, 2026 | Ro Khanna | D | Sell | $1,001 - $15,000 |
| Mar 3, 2026 | Gilbert Cisneros | D | Buy | $1,001 - $15,000 |
| Dec 11, 2025 | Gilbert Cisneros | D | Buy | $1,001 - $15,000 |
| Apr 17, 2025 | Gilbert Cisneros | D | Buy | $1,001 - $15,000 |
| Jan 29, 2025 | Gilbert Cisneros | D | Buy | $1,001 - $15,000 |
| Jan 24, 2024 | Josh Gottheimer | D | Buy | $1,001 - $15,000 |
| Aug 23, 2021 | Ro Khanna | D | Purchase | $1,001 - $15,000 |
| Jul 2, 2021 | Ro Khanna | D | Sale | $1,001 - $15,000 |
| Aug 19, 2019 | Greg Gianforte | R | Sale | $50,001 - $100,000 |
Across the 14 disclosed congressional trades in Agios Pharmaceuticals, Inc. (AGIO), members of Congress have reported 2 buys and 4 sells. The average 30-day alpha vs. the S&P 500 is 3.89%.
For fiscal year 2025, Agios Pharmaceuticals, Inc. reported revenue of $54.0M and net income of -$412.8M, per SEC filings.
Most recent reported quarter: Q2 FY2026 — revenue $65.5M, net income -$199.8M.
Figures come from SEC financial statement filings. The full annual and quarterly statement history is in the Financials tab above.